Filing Details

Accession Number:
0000899243-21-007201
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-02-18 19:09:26
Reporting Period:
2021-02-01
Accepted Time:
2021-02-18 19:09:26
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1631574 Wave Life Sciences Ltd. WVE Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1657765 Kyle Moran C/o Wave Life Sciences Ltd.,
733 Concord Ave.
Cambridge MA 02138
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Acquisiton 2021-02-01 50,000 $0.00 71,584 No 4 A Direct
Ordinary Shares Disposition 2021-02-16 1,722 $10.57 69,862 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Ordinary Shares Share Option (right to buy) Acquisiton 2021-02-01 50,000 $0.00 50,000 $10.48
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
50,000 2031-02-01 No 4 A Direct
Footnotes
  1. Consists of restricted share units (RSUs). The RSUs vest in two equal installments on February 15, 2022 and February 15, 2023.
  2. Includes 1,500 ordinary shares acquired under the issuer's 2019 Employee Share Purchase Plan (ESPP) on January 14, 2021.
  3. On February 16, 2021, the reporting person sold 1,722 ordinary shares solely to cover taxes associated with the vesting of RSUs on February 15, 2021. These sales were made pursuant to a 10b5-1 Trading Plan.
  4. The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $10.50 to $10.58 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
  5. The option vests as to 50% of the shares on February 15, 2022 and 50% on February 15, 2023.